Lilly’s Lower-Cost Zepbound Options Could Ease Patient Transition From Compounded GLP-1s

 
• By Cathy Kelly
  
The Zepbound line extension and price reductions are aimed to appeal to self-pay customers. (Shutterstock)
Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

SpotifyApple PodcastsWebsite

More from Distribution/Supply Chain

More from Geography